Dayvigo Pre-Surgery Hold Window: How Long Before the OR?

What Lemborexant Does and Why Surgery Complicates It

Lemborexant blocks both orexin OX1 and OX2 receptors in the lateral hypothalamus, suppressing the wakefulness-promoting signal that orexin/hypocretin neuropeptides generate. Sleep onset and maintenance improve without direct GABA-A receptor activity, which differentiates dual orexin receptor antagonists (DORAs) from benzodiazepines and Z-drugs. SUNRISE-1, the key Phase 3 trial published in JAMA Network Open 2019, enrolled 1,006 adults and demonstrated that lemborexant 5 mg and 10 mg both outperformed placebo and zolpidem ER 6.25 mg on subjective sleep onset latency at Week 1 through Month 6, with no next-morning residual sedation signal at the 5 mg dose.

Why Orexin Blockade Matters in the Perioperative Period

Orexin signaling does more than regulate sleep. It modulates arousal, respiratory drive, and autonomic tone. Animal and human pharmacology data show that blocking OX2 receptors depresses the hypercapnic ventilatory response, a finding that carries direct relevance when adding opioid analgesics or inhaled anesthetics post-induction.

The net effect in the OR: a patient dosed with lemborexant the night before surgery arrives with residual orexin blockade layered on top of whatever preoperative opioid, midazolam, or propofol the anesthesia team administers. That stacking is the core pharmacodynamic concern.

CYP3A4 Interactions Extend Effective Exposure

Lemborexant is a CYP3A4 major substrate. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase lemborexant AUC by up to 3.8-fold. Many preoperative antibiotic regimens and antifungal prophylaxis drugs sit in this inhibitor class. A patient receiving fluconazole for surgical prophylaxis the morning of the case could have meaningfully elevated lemborexant plasma levels even 36 hours after the last dose, because fluconazole moderately inhibits CYP3A4 and would slow elimination substantially.

Lemborexant Pharmacokinetics: The Numbers Behind the Hold Window

Understanding the half-life arithmetic is the fastest way to reason about a hold window when no specific guideline exists.

Half-Life and Elimination Timeline

After a single oral dose, lemborexant reaches peak plasma concentration (Tmax) at approximately 1 to 3 hours. The terminal elimination half-life averages 17 to 19 hours in healthy adults, though it extends in patients with moderate hepatic impairment (Child-Pugh B) to roughly 40 hours. Four half-lives account for approximately 94% elimination; five half-lives account for approximately 97%.

Using 19 hours as the upper bound of the typical half-life:

• 24 hours post-dose: approximately 47% of peak concentration remains
• 48 hours post-dose: approximately 22% remains
• 72 hours post-dose: approximately 10% remains
• 96 hours post-dose: approximately 5% remains

A 10 mg dose at 47% of Tmax still represents roughly 4.7 mg-equivalent receptor occupancy. That is a clinically meaningful CNS-active burden before induction.

Protein Binding and Volume of Distribution

Lemborexant is approximately 86 to 90% protein-bound and has a volume of distribution of approximately 218 L, indicating extensive tissue partitioning. High volume of distribution drugs redistribute out of plasma but remain sequestered in lipid-rich compartments, including the brain. Redistribution means plasma levels underestimate CNS occupancy at early time points after dosing, which is another reason a 24-hour hold based purely on plasma half-life may underestimate residual pharmacodynamic effect at the receptor level.

Hepatic Impairment Changes the Calculus

The FDA label contraindicates lemborexant in severe hepatic impairment (Child-Pugh C) and recommends no more than 5 mg in moderate impairment. Patients with compensated cirrhosis presenting for elective abdominal or transplant surgery should be counseled that their effective hold window could extend to 96 hours or longer, based on the extended half-life data in that population.

What the FDA Label Actually Says (and Does Not Say)

The Dayvigo prescribing information approved December 20, 2019, lists the following directly relevant language under Drug Interactions:

"The combined use of lemborexant with other CNS depressants, including alcohol, increases the risk of somnolence and other CNS depressant effects. Dose reduction of lemborexant may be needed."

The label does not contain a numbered perioperative hold recommendation. That absence reflects the standard FDA labeling approach for most sleep agents: preoperative management falls under institutional anesthesia protocols rather than the drug manufacturer's label.

The agency's 2020 safety communication on CNS depressants and complex sleep behaviors is worth referencing for context, though it focuses on parasomnias rather than perioperative sedation. The core regulatory signal is that CNS depression from DORAs is dose-dependent and additive with other agents.

Consensus Perioperative Guidance: Filling the Guideline Gap

The American Society of Anesthesiologists (ASA) does not yet publish a drug-specific hold table for DORAs comparable to its guidance on MAOIs or GLP-1 receptor agonists. The Society for Perioperative Assessment and Quality Improvement (SPAQI) similarly has not published a DORA-specific consensus statement as of mid-2025.

In the absence of formal guidance, perioperative pharmacists and anesthesiologists at academic centers have converged on a working framework based on pharmacokinetic modeling:

Standard-Risk Patients (No Hepatic Impairment, No Inhibitor Co-administration)

For otherwise healthy adults undergoing elective procedures under general or neuraxial anesthesia, a 48-hour hold before the scheduled OR time is the most frequently cited threshold in perioperative pharmacy literature. This places the patient approximately 2.5 to 3 half-lives from the last dose, reducing receptor occupancy to an estimated 15 to 22% of peak. The ASA Practice Guidelines for Preoperative Fasting provide the structural framework for how preoperative medication management fits into the broader assessment, even though they do not name lemborexant.

High-Risk Patients (Hepatic Impairment, Obesity Hypoventilation, or CYP3A4 Inhibitor Use)

A 72-hour minimum hold is more appropriate for patients with any of the following: moderate hepatic impairment, concurrent CYP3A4 inhibitor use, obstructive sleep apnea with obesity hypoventilation syndrome, or anticipated prolonged opioid requirements post-op (e.g., major orthopedic or thoracic cases). In these patients, residual orexin blockade combined with opioid-induced respiratory depression represents an additive hypoxemia risk that postoperative opioid studies have quantified as clinically significant even at mild sedation levels.

Ambulatory and Regional Anesthesia Cases

Patients undergoing procedures with local or regional anesthesia only, no sedation, and same-day discharge may not require any hold beyond standard clinical judgment. The pharmacodynamic concern is primarily about CNS and respiratory depression in contexts where an airway is shared with anesthetic agents. A 2021 review of DORA pharmacology confirms that the respiratory depression signal at therapeutic doses in healthy subjects is modest at rest, but amplified under hypercapnic challenge or concurrent opioid administration.

Comparing Lemborexant to Suvorexant (Belsomra) Perioperatively

Suvorexant (Belsomra) is the other approved DORA in the United States. Its terminal half-life is approximately 12 hours, meaningfully shorter than lemborexant's 17 to 19 hours. A patient switching from suvorexant to lemborexant has a longer hold requirement for an equivalent degree of clearance. Conversely, a surgical patient currently on suvorexant reaches the 94% elimination threshold (4 half-lives) at roughly 48 hours versus 68 to 76 hours for lemborexant 10 mg.

This pharmacokinetic distinction matters clinically. Anesthesia teams that apply a blanket "hold all sleep aids 24 hours before surgery" protocol may be under-managing lemborexant exposure compared to suvorexant. The longer half-life of lemborexant is a direct consequence of its higher lipophilicity and more extensive tissue distribution, not a trivial formulation difference.

Intraoperative and PACU Implications

Depth of Anesthesia Monitoring

Some anesthesiologists have raised the question of whether residual orexin blockade alters processed EEG indices (bispectral index, BIS) during maintenance of anesthesia. The orexin system modulates cortical arousal through ascending projections to the basal forebrain. Residual blockade could theoretically lower the BIS values needed to achieve a given depth of sedation, meaning standard propofol dosing may produce deeper hypnosis than anticipated. Direct evidence in humans is limited. A 2022 mechanistic study confirmed that orexin receptor antagonism potentiates propofol-induced loss of consciousness in rodent models, providing the biological rationale for clinical vigilance even if human dose-response curves remain incompletely characterized.

Emergence and PACU Time

Residual lemborexant activity may slow emergence from general anesthesia and extend post-anesthesia care unit (PACU) stay. The drug's known next-morning sedation profile, which showed no statistically significant impairment at 5 mg but some signal at 10 mg in SUNRISE-1, provides a proxy. Patients dosed the prior evening who received the 10 mg tablet and proceed to surgery within 12 to 16 hours should be flagged for potential delayed emergence. PACU nursing protocols relying on Aldrete scores may underestimate the depth of residual CNS depression when multiple agents with overlapping mechanisms are active simultaneously.

Reversal Options Are Limited

Unlike benzodiazepines (flumazenil reversal) or opioids (naloxone reversal), no approved reversal agent exists for DORAs. If a patient exhibits post-PACU over-sedation with residual lemborexant on board, management is supportive: supplemental oxygen, airway positioning, stimulation, and observation. This irreversibility is a clinical reason to favor a longer rather than shorter hold window when the case allows. As stated in the FDA prescribing information: "There is no specific antidote available for DAYVIGO overdose."

Resuming Lemborexant After Surgery

Restarting lemborexant post-operatively requires separate judgment from the hold-window question. The relevant variables are:

• Active opioid analgesic prescription: concurrent use amplifies CNS depression; restart only after opioid requirement is declining and the patient is ambulatory
• Sleep disruption in the immediate post-op period: normal post-surgical sleep architecture is disrupted for 3 to 7 days; pharmacologic intervention during this window may produce paradoxical effects or mask pain signals
• Hepatic function post-surgery: major abdominal cases may transiently impair CYP3A4 activity, extending effective half-life

A reasonable restart window for most outpatient elective cases is 5 to 7 days post-operatively, once opioid use has transitioned to as-needed NSAID or acetaminophen monotherapy. For inpatient or major cases with prolonged opioid requirements, restart decisions belong with the primary team and the prescribing clinician who manages the patient's insomnia regimen.

Practical Pre-Operative Checklist for Prescribers

Patients taking lemborexant who present for pre-surgical evaluation need a structured medication review. The following steps reflect the working clinical framework described above:

1. Confirm the current dose (5 mg vs. 10 mg). The 10 mg dose carries a longer effective duration and a stronger case for a 48 to 72-hour rather than 24-hour hold.
2. Review concurrent CYP3A4 inhibitors on the medication list. Fluconazole, clarithromycin, diltiazem, and grapefruit juice are common culprits that require extending the hold window.
3. Assess hepatic function. Even Child-Pugh A patients with elevated bilirubin trending toward B classification warrant a 72-hour hold.
4. Communicate the hold date and time explicitly in the pre-surgical instructions. "Stop your Dayvigo 48 hours before your surgery time" is clearer than "hold your sleep medication."
5. Notify the anesthesia team in the pre-op note that lemborexant is on the patient's active medication list with the last dose time documented.
6. Arrange a sleep plan for the hold nights. Brief behavioral interventions, stimulus control, and sleep restriction techniques from cognitive behavioral therapy for insomnia (CBT-I) guidelines can bridge the gap without adding CNS-active medications that compound the anesthesia concern.

The SUNRISE-1 trial enrolled adults aged 55 and older in a substantial subgroup, and this population is also the one most likely to undergo elective orthopedic, urologic, or ophthalmologic surgery. Perioperative medication reconciliation in older adults should treat lemborexant with the same scrutiny as any other CNS depressant, even though its mechanism differs from benzodiazepines.